Marshall Wace LLP Raises Holdings in Penumbra, Inc. (NYSE:PEN)

Marshall Wace LLP grew its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 2,312.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 43,952 shares of the company's stock after purchasing an additional 42,130 shares during the quarter. Marshall Wace LLP owned approximately 0.11% of Penumbra worth $10,438,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Baillie Gifford & Co. grew its stake in Penumbra by 23.4% during the fourth quarter. Baillie Gifford & Co. now owns 730,233 shares of the company's stock valued at $173,416,000 after acquiring an additional 138,387 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Penumbra by 8.2% during the 3rd quarter. Franklin Resources Inc. now owns 319,232 shares of the company's stock worth $67,473,000 after acquiring an additional 24,091 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Penumbra by 39.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 299,397 shares of the company's stock valued at $71,831,000 after purchasing an additional 85,284 shares during the period. Artisan Partners Limited Partnership increased its position in shares of Penumbra by 1.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 296,058 shares of the company's stock worth $70,308,000 after acquiring an additional 5,470 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Penumbra by 0.6% in the fourth quarter. Bank of New York Mellon Corp now owns 294,620 shares of the company's stock valued at $69,966,000 after acquiring an additional 1,823 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors.

Insider Activity at Penumbra

In related news, CFO Maggie Yuen sold 2,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $286.00, for a total transaction of $572,000.00. Following the completion of the transaction, the chief financial officer now directly owns 15,243 shares of the company's stock, valued at $4,359,498. This trade represents a 11.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas Wilder sold 360 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $264.58, for a total transaction of $95,248.80. Following the sale, the director now owns 4,533 shares of the company's stock, valued at approximately $1,199,341.14. This trade represents a 7.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 128,446 shares of company stock worth $35,959,193 in the last ninety days. 5.00% of the stock is owned by company insiders.

Penumbra Trading Up 0.8 %

NYSE:PEN traded up $2.25 on Friday, reaching $300.50. The company's stock had a trading volume of 608,778 shares, compared to its average volume of 424,593. The firm has a market cap of $11.64 billion, a PE ratio of 883.82, a PEG ratio of 2.83 and a beta of 0.56. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The business's 50-day moving average price is $276.99 and its two-hundred day moving average price is $255.22. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. The firm had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. Equities research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PEN. Wells Fargo & Company upped their target price on Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a research report on Thursday. Robert W. Baird raised their price target on shares of Penumbra from $316.00 to $325.00 and gave the company an "outperform" rating in a research note on Thursday. BTIG Research restated a "buy" rating on shares of Penumbra in a report on Thursday. Royal Bank of Canada upped their target price on shares of Penumbra from $315.00 to $330.00 and gave the company an "outperform" rating in a research report on Thursday. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research note on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $302.40.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.